NDA Accepted for Filing by the FDA for Antisense Oligonucleotide Viltolarsen (NS-065/NCNP-01)

KYOTO, Japan and PARAMUS, NJ: February 7, 2020 - Nippon Shinyaku Co., Ltd. (President, Shigenobu Maekawa) and NS Pharma, Inc. (President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku, announced today that the U.S. Food& Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news